Extracorporeal Membrane Oxygenation Market Research Report and Outlook by 2028

The extracorporeal membrane oxygenation (ECMO) market is anticipated to grow from US$ 546.73 million in 2021 to US$ 677.64 million by 2028, reflecting a compound annual growth rate (CAGR) of 3.1% from 2022 to 2028.

This report outlines the significant factors propelling market growth and identifies key players along with their advancements. The expansion of the extracorporeal membrane oxygenation market is largely driven by the increasing incidence of cardiovascular diseases and respiratory failures, alongside the rising use of ECMO in lung transplant procedures. Nevertheless, complications related to ECMO present challenges that may impede market growth.

Increasing Incidence of Cardiovascular Diseases and Respiratory Failures Fuels ECMO Market Expansion

Extracorporeal membrane oxygenation serves as a heart-lung bypass machine, utilized in treating cardiovascular ailments and respiratory failures. Annually, millions succumb to cardiovascular diseases (CVDs) globally. In Europe, CVDs are the leading cause of death, accounting for 45% of fatalities in the region and 37% within the European Union (EU). The 'Global Burden of Disease Study 2019' indicated that CVDs were among the top causes of death in Asia, resulting in 10.8 million deaths (35% of total deaths) that year. According to the 2022 Heart Disease & Stroke Statistical Update Fact Sheet, an estimated 119.1 million individuals died from CVDs worldwide in 2020. The same report noted that the global prevalence of stroke and ischemic stroke reached 89.1 million and 68.2 million, respectively, in 2020. North America also reports high rates of CVDs; the National Center for Chronic Disease Prevention and Health Promotion noted that approximately 697,000 individuals died from heart disease in the US. The American Heart Association projects that by 2035, over 130 million people in the US (45.1% of the population) will be affected by some form of cardiovascular disease. Furthermore, the National Library of Medicine reported that around 400,000 coronary artery bypass grafting (CABG) surgeries are performed annually in the US.

Chronic obstructive pulmonary disease (COPD) obstructs airflow from the lungs, potentially leading to respiratory failure. This life-threatening condition results in millions of deaths worldwide. The World Health Organization (WHO) identified COPD as the third leading cause of death, with 3.23 million fatalities globally in 2019. Notably, about 90% of COPD-related deaths occur in low- and middle-income nations. The Centers for Disease Control and Prevention (CDC) reported that in 2020, COPD was the sixth leading cause of death in the US. Consequently, the rising rates of cardiovascular diseases and respiratory failures are significant factors driving the growth of the ECMO market.

The global ECMO market is categorized by modality into venoarterial ECMO, venovenous ECMO, and arteriovenous ECMO. The venoarterial ECMO segment dominated the market in 2021 and is projected to grow at a CAGR of 3.1% during the forecast period. Venoarterial (VA) ECMO supports both the heart and lungs by circulating blood through a circuit without passing through the heart. This method extracts blood from a large vein and returns it to a large artery, ensuring that oxygen-rich blood circulates throughout the body even when the heart is unable to pump effectively. VA ECMO has gained widespread application over the past decade, proving to be an effective treatment option for refractory cardiogenic shock from various causes. It has shown promising outcomes in cases of in-hospital cardiac arrest, with survival rates and favorable neurological outcomes reported between 20% and 40%.

In terms of application, the global ECMO market is divided into respiratory and cardiology segments. The respiratory segment held a larger market share in 2021, as ECMO is utilized for patients recovering from lung failure. Conditions such as acute respiratory distress syndrome (ARDS), pulmonary embolism, and COVID-19 are among the lung diseases treated with ECMO. This technology can sustain patients in the complete absence of lung function. However, the cardiology segment is expected to grow at a CAGR of 3.6% during the forecast period. ECMO is also employed to assist patients with heart diseases awaiting organ transplants, and it is used in treating heart attacks (acute myocardial infarction), decompensated cardiomyopathy, and heart failure. According to WHO data, CVDs accounted for approximately 17.9 million deaths in 2019, representing 32% of all global fatalities. The increasing prevalence of cardiovascular diseases is likely to drive demand for ECMO machines in the years ahead.

Key sources referenced in the preparation of this report on the ECMO market include the Food and Drug Administration, the Ministry of Statistics and Program Implementation, the National Institute of Statistics and Geography, and the National Medical Products Administration.